RET splice site variants in medullary thyroid carcinoma

Daryoush Saeed-Vafa1, Kyriakos Chatzopoulos1, Juan Hernandez-Prera1

  • 1H. Lee Moffitt Cancer Center, Tampa, FL, United States.

Frontiers in Genetics
|April 3, 2024
PubMed

Insights

Medullary thyroid carcinoma (MTC) frequently harbors RET splice site variants (SSVs). These RET SSVs were found in all MTC cases studied, distinguishing them from other cancers and suggesting a potential diagnostic role.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Medullary thyroid carcinoma (MTC) is an aggressive malignancy often driven by mutations in the RET proto-oncogene.
  • Splice site variants (SSVs) can alter mRNA processing and protein function, but their role in MTC is not well-established.

Purpose of the Study:

  • To investigate the prevalence and diagnostic potential of RET splice site variants (SSVs) in medullary thyroid carcinoma (MTC).

Main Methods:

  • Next-generation sequencing data from 3,624 cancer cases, including 25 MTCs, were analyzed for RET SSVs.
  • Fisher exact tests were used to compare the frequency of RET SSVs between MTC and other cancer types.

Main Results:

  • All 25 MTC cases (100%) exhibited at least one of the two most common RET SSVs.
  • In contrast, only 0.3% of 3,599 non-MTC cancer cases harbored these common RET SSVs (p < 0.00001).
  • Notably, 4 MTC cases lacked other identified RET driver mutations, highlighting the significance of SSVs.

Conclusions:

  • The high prevalence of specific RET SSVs in MTC, coupled with their rarity in other cancers, suggests they are strong distinguishing markers for MTC.
  • Further research is warranted to elucidate the pathogenic role of these RET SSVs in MTC development.